<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01902186</url>
  </required_header>
  <id_info>
    <org_study_id>RALBAT</org_study_id>
    <nct_id>NCT01902186</nct_id>
  </id_info>
  <brief_title>Bone Mineral Density Changes in HIV-positive Females With Osteopenia Switching to Raltegravir</brief_title>
  <acronym>RALBAT</acronym>
  <official_title>Switching HIV-positive Women on Tenofovir/Emtricitabine Plus Boosted Atazanavir to RALtegravir Plus Boosted ATazanavir: A Pilot Randomized Clinical Trial Investigating 48-weeks Changes in Bone Mineral Density</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Giovanni Di Perri</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Turin, Italy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Milan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Turin, Italy</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Given the high prevalence of bone alteration in the course of HIV infection or antiretroviral
      treatment and the favourable properties of raltegravir the investigators designed this pilot
      randomized and controlled study. Adult female HIV-positive patients on successful treatment
      with tenofovir/emtricitabine plus atazanavir plus ritonavir will be randomized either to
      continue such a regimen or to switch to raltegravir plus atazanavir plus ritonavir. Bone
      mineral density changes will be compared in the two groups at 48 weeks: the hypothesis is
      that removing tenofovir and using tenofovir will increase bone mineral density at 48 weeks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective is to assess the improvement in Bone Mineral Density and markers of bone
      turnover in women on TDF/FTC (tenofovir disoproxil fumarate/ emtricitabine)+ ATV/r
      (atazanavir/ritonavir) in a switch arm (RAL (raltegravir) + ATV/r) vs. an unchanged arm
      (TDF/FTC + ATV/r).

      The clinical hypothesis is that removing tenofovir (associated to a boosted PI, and therefore
      in the worst clinical scenario) in both pre-menopausal and menopausal women could be
      beneficial and being associated with reduced bone mineral density loss measured by DEXA
      (densitometry)scan scores and markers of bone turnover. The underlying mechanism is believed
      to be the reduction in hyper-phosphaturia induced by proximal tubular dysfunction: therefore
      measuring renal tubular markers and hormones involved in calcium and phosphorus homeostasis
      (such as vitamin D and parathormone) will explain the suspected mechanism.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2014</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Variations from baseline in DEXA-measured bone mineral density (t-score, spine and femur)</measure>
    <time_frame>48 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>variations from baseline in CTX (C-terminal telopeptide of type I collagen) and OC (Osteocalcin)</measure>
    <time_frame>24 and 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the variation in renal function</measure>
    <time_frame>48 weeks</time_frame>
    <description>glomerular filtration rate, urinary markers of tubular dysfunction (nondiabetic glucosuria, altered resorption of phosphorus, hyperaminoaciduria, b2-micro-globuline excretion and abnormal uric acid excretion.) and urinary retinol binding protein</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Cholesterol changes at 48 weeks in the two arms</measure>
    <time_frame>48 weeks</time_frame>
    <description>Changes in Cholesterol levels in the two arms</description>
  </other_outcome>
  <other_outcome>
    <measure>Triglycerides changes in the two arms</measure>
    <time_frame>48 weeks</time_frame>
    <description>Changes in Tryglicerdies levels in the two arms</description>
  </other_outcome>
  <other_outcome>
    <measure>Glucose Fasting Levels changes in the two arms</measure>
    <time_frame>48 weeks</time_frame>
    <description>Changes in Glucose Fasting Levels in the two arms</description>
  </other_outcome>
  <other_outcome>
    <measure>Insulin changes in the two arms</measure>
    <time_frame>48 weeks</time_frame>
    <description>Changes in Insulin levels in the two arms</description>
  </other_outcome>
  <other_outcome>
    <measure>Parathyroid hormone changes in the two arms</measure>
    <time_frame>48 weeks</time_frame>
    <description>Changes in Parathyroid hormone levels in the two arms</description>
  </other_outcome>
  <other_outcome>
    <measure>Vitamine D (25-OH-Vitamine D) changes in the two arms</measure>
    <time_frame>48 weeks</time_frame>
    <description>Changes in Vitamine D (25-OH-Vitamine D)levels in the two arms</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">66</enrollment>
  <condition>HIV Infection</condition>
  <condition>Osteopenia</condition>
  <arm_group>
    <arm_group_label>raltegravir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>raltegravir and atazanavir and ritonavir</description>
  </arm_group>
  <arm_group>
    <arm_group_label>tenofovir/emtricitabine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>tenofovir/emtricitabine and atazanavir and ritonavir</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>raltegravir and atazanavir and ritonavir</intervention_name>
    <description>switch tenofovir/emtricitabine to raltegravir</description>
    <arm_group_label>raltegravir</arm_group_label>
    <other_name>Isentress (raltegravir)</other_name>
    <other_name>Reyataz (atazanavir)</other_name>
    <other_name>Norvir (ritonavir)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tenofovir/emtricitabine and atazanavir and ritonavir</intervention_name>
    <description>no change in antiretroviral treatment; patients will continue their regimen (tenofovir/emtricitabine and atazanavir and ritonavir)</description>
    <arm_group_label>tenofovir/emtricitabine</arm_group_label>
    <other_name>tenofovir/emtricitabine (Truvada)</other_name>
    <other_name>atazanavir (Reyataz)</other_name>
    <other_name>ritonavir (norvir)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult HIV-positive female patients;

          -  osteopenia (t-score from -1 to -2.5);

          -  On antiretroviral treatment with tenofovir/emtricitabine and atazanavir/ritonavir
             (300/100 mg) for at least six months;

          -  Plasma HIV RNA below 50 copies/ml since six months;

          -  Premenopausal women: female patients at any phase of the reproductive period with
             regular menstrual cycles and normal FSH (&lt; 25 ng/mL) That would probably exclude
             patients with ovarian or endocrinological dysfunctions. Pre and postmenopausal should
             be therefore well-characterized.

          -  Women in menopausal period (the menopause was defined as 12 months of amenorrhoea
             without any pathological or physiological cause and using the endocrinological
             definition of ovary insufficiency (LH (Luteic hormone) &gt;25ng/mL, FSH (follicule
             stimulating hormone)&gt;25ng/mL and E2 (Estradiol)&lt;30ng/mL).

          -  Each premenopausal sexually active subject of child-bearing potential must agree to
             use a medically accepted method of contraception while receiving protocol-specified
             medication and for 3 months after stopping the medication.Medically accepted methods
             of contraception include condoms (male or female) with or without a spermicidal agent,
             diaphragm or cervical cap with spermicide, medically prescribed IUD (intrauterine
             device), inert or copper-containing IUD, hormone-releasing IUD, systemic hormonal
             contraceptive, and surgical sterilization (eg, hysterectomy or tubal ligation).

          -  Postmenopausal women are not required to use contraception.

        Exclusion Criteria:

          -  History or current evidence of any condition, therapy, laboratory abnormality or other
             circumstance that might confound the results of the study, or interfere with the
             patient's participation for the full duration of the study, such that it is not in the
             best interest of the patient to participate.

          -  Documented resistance to Raltegravir or/and Atazanavir.

          -  Patient with significant hypersensitivity or other contraindication to any of the
             components of the study drugs.

          -  Patient has a current (active) diagnosis of acute hepatitis due to any cause

          -  Patient with coinfection HIV/HBV (Human Hepatitis virus B)

          -  Liver cirrhosis

          -  Osteoporosis (t-score less than 2.5).

          -  Secondary endocrinological cause of low BMD (Bone mineral density)

          -  Chronic steroid intake;

          -  Chronic kidney disease (estimated glomerular filtration rate below 60 ml/min);

          -  Concomitant use of bisphosphonate.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giovanni Di Perri, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Turin, Italy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andrea Calcagno, MD</last_name>
    <phone>+390114393884</phone>
    <email>andrea.calcagno@unito.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Milano</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stefano Rusconi, MD</last_name>
      <email>stefano.rusconi@unimi.it</email>
    </contact>
    <investigator>
      <last_name>Massimo Galli, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stefano Rusconi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Torino</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Calcagno, MD</last_name>
      <phone>+390114393884</phone>
      <email>andrea.calcagno@unito.it</email>
    </contact>
    <investigator>
      <last_name>Stefano Bonora, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Giovanni Di Perri, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrea Calcagno, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 10, 2013</study_first_submitted>
  <study_first_submitted_qc>July 17, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 18, 2013</study_first_posted>
  <last_update_submitted>May 10, 2016</last_update_submitted>
  <last_update_submitted_qc>May 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Turin, Italy</investigator_affiliation>
    <investigator_full_name>Giovanni Di Perri</investigator_full_name>
    <investigator_title>Full professor of Infectious Diseases</investigator_title>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>osteopenia</keyword>
  <keyword>t-score</keyword>
  <keyword>DEXA</keyword>
  <keyword>tenofovir</keyword>
  <keyword>raltegravir</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Bone Diseases, Metabolic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Atazanavir Sulfate</mesh_term>
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Raltegravir Potassium</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

